Specific Targeting of Mesothelin-Expressing Malignant Cells Using Nanobody-Functionalized Magneto-Fluorescent Nanoassemblies
Tina Briolay,Judith Fresquet,Damien Meyer,Brigitte Kerfelec,Patrick Chames,Eléna Ishow,Christophe Blanquart
DOI: https://doi.org/10.2147/ijn.s435787
IF: 7.033
2024-01-21
International Journal of Nanomedicine
Abstract:Tina Briolay, 1 Judith Fresquet, 1 Damien Meyer, 2 Brigitte Kerfelec, 2 Patrick Chames, 2 Eléna Ishow, 3 Christophe Blanquart 1 1 Nantes Université, INSERM UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, F-44000, France; 2 Aix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille, France; 3 Nantes Université, CNRS, CEISAM, UMR 6230, Nantes, F-44000, France Correspondence: Christophe Blanquart, CRCI2NA, INSERM UMR 1307/CNRS UMR 6075, IRS-UN, 8 Quai Moncousu, BP70721, Cedex 1, Nantes, 44007, France, Tel +33 228 080 238, Email Introduction: Most current anti-cancer therapies are associated with major side effects due to a lack of tumor specificity. Appropriate vectorization of drugs using engineered nanovectors is known to increase local concentration of therapeutic molecules in tumors while minimizing their side effects. Mesothelin (MSLN) is a well-known tumor associated antigen overexpressed in many malignancies, in particular in malignant pleural mesothelioma (MPM), and various MSLN-targeting anticancer therapies are currently evaluated in preclinical and clinical assays. In this study, we described, for the first time, the functionalization of fluorescent organic nanoassemblies (NA) with a nanobody (Nb) targeting MSLN for the specific targeting of MSLN expressing MPM cancer cells. Methods: Cell lines from different cancer origin expressing or not MSLN were used. An Nb directed against MSLN was coupled to fluorescent NA using click chemistry. A panel of endocytosis inhibitors was used to study targeted NA internalization by cells. Cancer cells were grown in 2D or 3D and under a flow to evaluate the specificity of the targeted NA. Binding and internalization of the targeted NA were studied using flow cytometry, confocal microscopy and transmission electron microscopy. Results: We show that the targeted NA specifically bind to MSLN-expressing tumor cells. Moreover, such functionalized NA appear to be internalized more rapidly and in significantly larger proportions compared to naked ones in MSLN+ MPM cells, thereby demonstrating both the functionality and interest of the active targeting strategy. We demonstrated that targeted NA are mainly internalized through a clathrin-independent/dynamin-dependent endocytosis pathway and are directed to lysosomes for degradation. A 3D cell culture model based on MSLN-expressing multicellular tumor spheroids reveals NA penetration in the first superficial layers. Conclusion: Altogether, these results open the path to novel anticancer strategies based on MSLN-activated internalization of NA incorporating drugs to promote specific accumulation of active treatments in tumors. Keywords: mesothelin, targeting, nanoassemblies, nanobody, cancer Malignant pleural mesothelioma (MPM) is an aggressive cancer of the pleura that usually develops 3 to 4 decades following exposure to asbestos. It is a relatively rare disease that is typically associated with a poor prognosis, being responsible for approximately 30,000 annual deaths worldwide ( https://gco.iarc.fr/today/data/factsheets/cancers/18-Mesothelioma-fact-sheet.pdf ). For years, the first-line treatment of MPM has consisted of systemic chemotherapy regimens including a platinum-derivate (either cisplatin or carboplatin) and an antimetabolite (pemetrexed), but the outcomes remain unsatisfactory. 1,2 New therapeutic alternatives are currently being tested in clinical trials, such as immune checkpoint inhibitors 3 and targeted therapies. 4 The recent approval of nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4) as first-line treatment of advanced unresectable mesothelioma, the first Food and Drug Administration (FDA) approval since pemetrexed and cisplatin, represents a major progress in MPM management. 4,5 However, the median overall survival of patients, despite treatment with this protocol, remains low (around 18 months). There is therefore an urgent need for new therapeutic alternatives to treat MPM patients. The efficiency of anti-cancer therapies and the development of new molecules are usually limited by systemic toxicity and solubility concerns. To overcome these problems, strategies of vectorization have been developed to increase circulation time of active molecules in blood, reduce their toxicity and increase their accumulation in tumors. 6 This approach was notably evaluated in MPM using an untargeted liposomal doxorubicin. 7,8 The efficiency of this strategy was however limited by the still insufficient accumulation of the active molecule in the tumors. 7,8 Active targeting of nanovectors to tumors, mostly thanks to antibody fr -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology